In drug development it is critical to understand the bioavailability, particularly orally, of a candidate. Poor oral bioavailability can result in inconsistent exposure, multiplied by a lack of appreciation for the candidate's specific bioavailability-limiting properties. Absorption Systems scientists have the tools and expertise to determine a drug compound's absorption rate and barriers to bioavailability, including our exclusive ABT model, which can distinguish between first-pass metabolism and absorption.
Bioavailability and Exposure Assays
Dose Vehicle Assessment
Brain to Plasma Ratio
Species: Mouse, Rat, Rabbit, Dog, Monkey, Minipig
Dose Routes: IV, Oral, Subcutaneous, IP, Buccal, Sublingual
Business Development Manager